KTTA – pasithea therapeutics corp. (US:NASDAQ)
Stock Stats
News
Pasithea Therapeutics (KTTA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $3.00 price target on the stock.
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) [Yahoo! Finance]
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Pasithea Therapeutics (KTTA) was downgraded by Zacks Research from "hold" to "strong sell".
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity [TheStreet.com]
Form SCHEDULE 13G Pasithea Therapeutics Filed by: Funicular Funds, LP
Form 3 Pasithea Therapeutics For: Apr 09 Filed by: Coastlands Capital LP
Form SCHEDULE 13G Pasithea Therapeutics Filed by: Opaleye Management Inc.
Form 10-K Pasithea Therapeutics For: Dec 31
Form SCHEDULE 13G Pasithea Therapeutics Filed by: Coastlands Capital LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.